journal article·2021-01-20

Hierarchically Releasing Bio-Responsive Nanoparticles for Complete Tumor Microenvironment Modulation via TGF-β Pathway Inhibition and TAF Reduction

Jun Zhang, Tiantian Zuo, Jie Yang, Zongwei Hu, Zhihua Wang, Rui Xu, Siyu Ma, Yawen Wei, Qi Shen

Publisher page

Abstract

The aggressive progression of breast cancer is impacted significantly by the tumor microenvironment (TME). The current chemotherapy normally causes cytotoxicity to tumor cells, while does not effectively modulate the TME. Thus, the chemotherapy effect of breast cancer is usually dissatisfactory. In this study, a kind of hierarchically releasing bio-responsive nanoparticles (R(D)/H(S) NPs), constructed by β-cyclodextrin-grafted heparin and pH-sensitive pseudorotaxane, were investigated to enhance the breast cancer chemotherapeutic efficacy through TME modulation. Doxorubicin (DOX) and transforming growth factor-β (TGF-β) receptor inhibitor (SB431542) loaded onto R(D)/H(S) NPs were released rapidly for the respective response to low pH in endosomes/lysosomes and heparanase (HPSE) in TME. Our results showed that R(D)/H(S) NPs effectively inhibited the formation of tumor-associated fibroblasts (TAFs) and reduced TGF-β and collagen I secretion. Besides, the immunosuppressive microenvironment was effectively reversed into immunogenic, characterized by increased CD8+ and CD4+ T cell infiltration, which distinctly inhibited breast cancer metastasis. Therefore, R(D)/H(S) NPs remodeled the TME by downregulating TAFs, TGF-β, and collagen I; activating the immune microenvironment; and then amplifying the chemotherapeutic efficacy of DOX.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Immune cells in cancer · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China

Funding

Shanghai Jiao Tong University · National Natural Science Foundation of China

References (65)

Show source-provided references
1. 10.1016/j.canlet.2015.07.03910.1016/j.canlet.2015.07.039 ↗
2. 10.1159/00043049910.1159/000430499 ↗
3. 10.1631/jzus.b160057910.1631/jzus.b1600579 ↗
4. 10.1007/s10555-012-9415-310.1007/s10555-012-9415-3 ↗
5. 10.3390/cancers802001910.3390/cancers8020019 ↗
6. 10.1158/1078-0432.ccr-11-311410.1158/1078-0432.ccr-11-3114 ↗
7. 10.1056/NEJM19861225315260610.1056/NEJM198612253152606 ↗
8. 10.4161/cam.2041910.4161/cam.20419 ↗
9. Huang T.-X. · Am. J. Cancer Res. · 2019 · 9 · 1889
10. 10.1177/153303381987990510.1177/1533033819879905 ↗
11. 10.1126/science.119530010.1126/science.1195300 ↗
12. 10.1002/path.495810.1002/path.4958 ↗
13. 10.1073/pnas.101380510710.1073/pnas.1013805107 ↗
14. 10.1016/j.semcancer.2013.12.00510.1016/j.semcancer.2013.12.005 ↗
15. 10.1016/j.immuni.2019.03.02410.1016/j.immuni.2019.03.024 ↗
16. 10.1073/pnas.060238210310.1073/pnas.0602382103 ↗
17. Yang K. · Am. J. Transl. Res. · 2019 · 11 · 5858
18. 10.1007/978-3-319-42023-3_410.1007/978-3-319-42023-3_4 ↗
19. 10.1021/acsnano.8b0589310.1021/acsnano.8b05893 ↗
20. 10.21037/atm.2019.09.6810.21037/atm.2019.09.68 ↗
21. 10.3389/fimmu.2018.0039810.3389/fimmu.2018.00398 ↗
22. 10.1016/j.tips.2017.10.00910.1016/j.tips.2017.10.009 ↗
23. 10.1002/advs.20180207010.1002/advs.201802070 ↗
24. 10.7150/thno.2943110.7150/thno.29431 ↗
25. 10.1371/journal.pone.012648310.1371/journal.pone.0126483 ↗
26. 10.1016/j.matbio.2017.08.00510.1016/j.matbio.2017.08.005 ↗
27. 10.1039/c9tb01702j10.1039/c9tb01702j ↗
28. 10.1002/wnan.145210.1002/wnan.1452 ↗
29. 10.1002/jbm.b.3351910.1002/jbm.b.33519 ↗
30. 10.1002/smll.20140139710.1002/smll.201401397 ↗
31. 10.1021/acs.bioconjchem.5b0054510.1021/acs.bioconjchem.5b00545 ↗
32. 10.1021/bc025613a10.1021/bc025613a ↗
33. 10.1016/j.polymer.2009.07.00610.1016/j.polymer.2009.07.006 ↗
34. 10.1021/ja104501a10.1021/ja104501a ↗
35. 10.1021/bi301088910.1021/bi3010889 ↗
36. 10.1016/j.polymer.2013.07.04410.1016/j.polymer.2013.07.044 ↗
37. 10.1021/acsami.6b1139010.1021/acsami.6b11390 ↗
38. 10.1016/j.ijpharm.2019.02.00210.1016/j.ijpharm.2019.02.002 ↗
39. 10.1016/j.jconrel.2015.08.02710.1016/j.jconrel.2015.08.027 ↗
40. 10.1038/onc.2012.29510.1038/onc.2012.295 ↗
41. 10.1016/j.nano.2018.02.01210.1016/j.nano.2018.02.012 ↗
42. 10.1021/acsami.5b0121310.1021/acsami.5b01213 ↗
43. 10.1371/journal.pone.005217510.1371/journal.pone.0052175 ↗
44. 10.1002/mabi.20160007110.1002/mabi.201600071 ↗
45. 10.1021/bc200504v10.1021/bc200504v ↗
46. 10.1186/1471-2121-14-3210.1186/1471-2121-14-32 ↗
47. 10.1038/cdd.2014.21610.1038/cdd.2014.216 ↗
48. 10.3892/ijo.2015.306010.3892/ijo.2015.3060 ↗
49. 10.3390/cancers1111176610.3390/cancers11111766 ↗
50. 10.1007/s00253-012-3967-610.1007/s00253-012-3967-6 ↗
51. 10.1016/j.actbio.2016.02.02110.1016/j.actbio.2016.02.021 ↗
52. 10.1111/j.1745-7270.2005.00108.x10.1111/j.1745-7270.2005.00108.x ↗
53. 10.1073/pnas.162062611410.1073/pnas.1620626114 ↗
54. 10.1007/978-1-4939-1661-0_110.1007/978-1-4939-1661-0_1 ↗
55. 10.1021/acsnano.7b0805110.1021/acsnano.7b08051 ↗
56. 10.1016/j.jtho.2016.05.02510.1016/j.jtho.2016.05.025 ↗
57. 10.12659/msm.90287010.12659/msm.902870 ↗
58. 10.1016/j.cellsig.2014.06.00210.1016/j.cellsig.2014.06.002 ↗
59. 10.1016/j.ijpharm.2019.03.03110.1016/j.ijpharm.2019.03.031 ↗
60. 10.1021/acsnano.6b0119910.1021/acsnano.6b01199 ↗
61. 10.1016/j.csbj.2018.07.00310.1016/j.csbj.2018.07.003 ↗
62. 10.3109/08977194.2015.101064510.3109/08977194.2015.1010645 ↗
63. 10.1038/nature2550110.1038/nature25501 ↗
64. 10.1146/annurev-immunol-032713-12025710.1146/annurev-immunol-032713-120257 ↗
65. 10.1016/j.it.2010.04.00210.1016/j.it.2010.04.002 ↗